Proteomics International Laboratories (PIQ) Stock Price, News & Analysis

Company Overview

Proteomics International Laboratories Limited operates as a medical technology company with a focus on the area of proteomics. It provides PromarkerD, a predictive test for diabetic kidney disease; and develops diagnostic tests for endometriosis and giardia. The company also offers analytical services, including specialist contract research. The company was founded in 2001 and is based in Perth, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 126,546 shs
• Average Volume: N/A
• Market Capitalization: A$79.91 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PIQ Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Proteomics International Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Proteomics International Laboratories investors own include Woolworths Group (WOW), Patrys (PAB), Insurance Australia Group (IAG) and Bendigo and Adelaide Bank (BEN).

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: ASX:PIQ
• CIK: N/A
• Web: www.proteomics.com.au
• Phone: 61 8 9389 1992
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): A($0.05)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -A$6.38 million
• Net Margins: -199.26%
• Pretax Margin: N/A
• Return on Equity: -86.38%
• Return on Assets: -40.22%

Debt

• Debt-to-Equity Ratio: 3.36
• Current Ratio: 10.13
• Quick Ratio: 2.51

Sales & Book Value

• Annual Sales: A$3.28 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 13.15
• Book Value: A$0.07 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 131,000,000
• Free Float: N/A
• Market Cap: A$79.91 million
• Optionable: Not Optionable
• Beta: 0.46